Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

Nicholas David James, Sarah Pirrie, Darren Barton, Janet Elizabeth Brown, Lucinda Billingham, Stuart I. Collins, Adam Daunton, Alison J. Birtle, Prabir Ranjan Chakraborti, Daniel Ford, Syed A. Hussain, Helen Jones, Ann Pope, Emilio Porfiri, John Martin Russell, Andrew Stanley, John Staffurth, Duncan McLaren, Chris Parker, James Wylie

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Issue number18
Publication statusPublished - 20 Jun 2013
Event49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, Israel
Duration: 31 May 20134 Jun 2013

Cite this